Clinical Trial Update: Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating infusion of allogeneic cord blood-derived CD19-specific T cells for leukemia and lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Allogeneic umbilical cord blood-derived CD19-specific T cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED